AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportRecursion Pharmaceuticals vs Tempus AI
VS
Recursion Pharmaceuticals
Enterprise
Tempus AI
Enterprise
Verdict by Category
Detailed category analysis is not available for this comparison.
Feature & Spec Matrix
Detailed Comparison24 Criteria
Complete side-by-side breakdown of specifications, capabilities, and feature parity
Swipe horizontally to compare features
Feature / Spec
Pricing Model
EnterpriseAI-enabled drug discovery and mapping (Recursion OS) — Custom biopharma enterprise partnership agreements only
EnterpriseGenomic sequencing, clinical data analytics, and precision medicine AI — Custom institutional agreements for healthcare systems and life sciences
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No self-serve access — enterprise pharma collaborations and data licensing via partnership team
No free plan — genomic tests ordered by physicians; enterprise and biopharma data partnerships via sales
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Major pharma companies and researchers needing AI-powered biology mapping, target discovery, and drug candidate generation at industrial scale through the Recursion OS platform
Oncologists, health systems, and biopharma companies needing AI-powered genomic profiling, precision medicine insights, clinical trial matching, and drug development data
Enterprise & Scalability
Difference
NASDAQ listed (RXRX), $500M+ in pharma partnership milestones earned, enterprise collaboration agreements with Roche/Genentech and Sanofi, automated biology and chemistry labs at industrial scale in Salt Lake City and Oxford, and data licensing for external researchers
CLIA-certified genomics laboratory, CAP accredited, HIPAA compliant, SOC 2 Type II, de-identified patient data network of 7M+ records, EHR integration via HL7/FHIR, biopharma licensing agreements, and enterprise analytics platform with dedicated clinical account management
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Recursion OS — AI-native end-to-end drug discovery platform integrating biology, chemistry, and clinical development
Supported
Supported
Industrial-scale automated labs in Salt Lake City and Oxford generating proprietary multimodal data
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-4881 for FAP — 53% polyp reduction in Phase 2, FDA registration discussions begun 2026
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-1245 (RBM39 degrader) in Phase 1/2 DAHLIA study for solid tumors
Difference
Recursion Pharmaceuticals Advantage
Not listed
REC-4539 (LSD1 inhibitor) — first patient dosed in Phase 1 ENLYGHT study 2026
Difference
Recursion Pharmaceuticals Advantage
Not listed
Sanofi partnership — $134M earned to date across 5 milestones
Difference
Recursion Pharmaceuticals Advantage
Not listed
Roche/Genentech Phenomaps — 1 trillion neuronal cells for neuroscience target discovery
Difference
Recursion Pharmaceuticals Advantage
Not listed
$500M+ in cumulative pharma partnership milestones earned to date
Difference
Recursion Pharmaceuticals Advantage
Not listed
Recursion Data — phenomics and biology maps licensed to external researchers and pharma
Supported
Supported
NASDAQ: RXRX — founded 2013; $74.7M revenue in 2025; acquired Exscientia in 2024
Supported
Supported
Comprehensive genomic profiling — solid tumor (xT), germline (xG), RNA (xR), liquid biopsy (xF), and expression (xE) testing
Difference
Not listed
Tempus AI Advantage
AI-powered clinical trial matching (TIME Trial) to improve enrollment rates and identify eligible patients
Difference
Not listed
Tempus AI Advantage
Tempus One — AI clinical assistant for real-time treatment insights and literature synthesis at point of care
Difference
Not listed
Tempus AI Advantage
Neuropsychiatry panel for pharmacogenomics and psychiatric medication response prediction
Difference
Not listed
Tempus AI Advantage
Cardiology ECG analysis AI for arrhythmia and cardiac condition detection
Difference
Not listed
Tempus AI Advantage
Algos platform for population health analytics across health system patient cohorts
Difference
Not listed
Tempus AI Advantage
CLIA-certified lab with CAP accreditation for clinical-grade genomic report delivery
Difference
Not listed
Tempus AI Advantage
Recursion Pharmaceuticals Pros & Cons
Pros
- $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
- Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
- Industrial-scale automated labs generate data no other company can replicate
- Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
- Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
- Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
- Cash runway guided into early 2028 — disciplined capital allocation
Cons
- Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
- Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
- Acquired Exscientia in 2024 — integration complexity and added operational overhead
- No approved drugs yet — clinical proof of concept still early stage
- Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Tempus AI Pros & Cons
Pros
- Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
- 7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
- Comprehensive genomic testing across 6 test types covering all major oncology applications
- Tempus One AI provides real-time clinical insights at the point of care
- TIME Trial dramatically improves clinical trial matching and enrollment rates
- 3,800+ employees and $8.79B total capital raised since founding
- Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease
Cons
- Enterprise and institutional pricing — not accessible to individual clinicians or small practices
- Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
- Genomic test turnaround requires laboratory processing time
- Data platform access and licensing requires formal agreements
- Some AI insights require institutional genomic data infrastructure to fully leverage
Head-to-Head Battle Cards
Popular Comparisons
Direct feature matrices, pricing breakdowns, and real-world benchmark duels
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare
AI Healthcare ToolsCompare